Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

TRITON3: A Multicenter, Randomized, Open Label Phase 3 Study of Rucaparib Versus Physician's Choice of Therapy for Patients With Metastatic Castration Resistant Prostate Cancer Associated With Homologous Recombination Deficiency

NCT02975934 is registered in ClinicalTrials.gov with pharmaand GmbH as lead sponsor.

NCT NCT02975934
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02975934 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
TRITON3: A Multicenter, Randomized, Open Label Phase 3 Study of Rucaparib Versus Physician's Choice of Therapy for Patients With Metastatic Castration Resistant Prostate Cancer Associated With Homologous Recombination Deficiency
Lead sponsor
pharmaand GmbH
Phase
Phase 3
Overall status
Completed
Start date
June 13, 2017
Completion date
August 8, 2024
Enrollment
405 (actual)
Sites
150

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic castration resistant prostate cancer